



## **Avicanna Secures Canadian Cannabinoid Research Licence at its Headquarters in Toronto's Discovery District**

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

**Toronto, Ontario – August 19, 2019** – Avicanna Inc. ("**Avicanna**" or the "**Company**") a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has received a research licence (the "**Research Licence**") from Health Canada. The Research Licence will allow Avicanna's research and development team to work with cannabinoid-based formulations and advanced pharmaceutical drug development at Avicanna's research and development headquarters located at the MaRS Discovery District in Toronto.

Aras Azadian, Chief Executive Officer of Avicanna commented "Attaining this licence will allow Avicanna's team of scientists to directly enhance and expedite research and development and intellectual property development projects while we concurrently execute via our ongoing collaborations, including with the University of Toronto, and at our subsidiaries' laboratories in Colombia. In this way, Avicanna has further fortified its leadership position in the cannabinoid-based pharmaceutical industry and will further leverage working with top Canadian researchers, clinicians and world class institutions, many of which are located meters away from the newly licensed lab."

### **About Avicanna**

Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

SOURCE Avicanna Inc.



## **Stay Connected**

For more information about Avicanna, visit [www.avicanna.com](http://www.avicanna.com), call 1-647-243-5283, or contact Setu Purohit, President by email [info@avicanna.com](mailto:info@avicanna.com).

## **Cautionary Note Regarding Forward-Looking Information and Statements**

*Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the Company's intended use of the Research Licence. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.*